TAXOL Drug Patent Profile

Which patents cover Taxol, and what generic alternatives are available?

Taxol is a drug marketed by Hq Spclt Pharma and is included in one NDA.

The generic ingredient in TAXOL is paclitaxel. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Taxol

A generic version of TAXOL was approved as paclitaxel by TEVA PHARMS on January 25^th, 2002.

Summary for TAXOL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	95
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TAXOL
DailyMed Link:	TAXOL at DailyMed

US Patents and Regulatory Information for TAXOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992		DISCN	Yes	No

Expired US Patents for TAXOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	5,496,804
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	5,641,803
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	6,150,398
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	6,096,331

EU/EMA Drug Approvals for TAXOL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Abraxane	paclitaxel	EMEA/H/C/000778Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Authorised	no	no	no	2008-01-11
ratiopharm GmbH	Pazenir	paclitaxel	EMEA/H/C/004441Pazenir monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Pazenir in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Authorised	yes	no	no	2019-05-06
Inceptua AB	Apealea	paclitaxel	EMEA/H/C/004154Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.	Authorised	no	no	no	2018-11-20
Norton Healthcare Ltd.	Paxene	paclitaxel	EMEA/H/C/000216Paxene is indicated for the treatment of patients with:• advanced AIDS-related Kaposi's sarcoma (AIDS-KS) who have failed prior liposomal anthracycline therapy;• metastatic carcinoma of the breast (MBC) who have failed, or are not candidates for standard anthracycline-containing therapy;• advanced carcinoma of the ovary (AOC) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment;• metastatic carcinoma of the ovary (MOC) after failure of platinum-containing combination therapy without taxanes as second-line treatment;• non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. Limited efficacy data supports this indication (see section 5.1).	Withdrawn	no	no	no	1999-07-19

International Patents for TAXOL

See the table below for patents covering TAXOL around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	MI931714
China	1237901
European Patent Office	1944019	Procédé pour la préparation des agents actifs stabilisés par protéine (Method for the preparation of protein stabilized pharmacologically active agents)
Japan	H07233064	ANTICANCER AGENT WHEREIN TACHYSOL IS ACTIVE INGREDIENT

Supplementary Protection Certificates for TAXOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1853250	132014902271575	Italy		PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220
1853250	PA2014022	Lithuania		PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
0961612	CA 2009 00036	Denmark		PRODUCT NAME: PACLITAXELALBUMIN
0961612	2009C/046	Belgium		PRODUCT NAME: PACLITAXEL ALBUMIN; AUTHORISATION NUMBER AND DATE: EU/1/07/428/001 20080111

Market Dynamics and Financial Trajectory for TAXOL (Paclitaxel)

Last updated: March 7, 2026

What is the current market size for TAXOL?

The global paclitaxel market was valued at approximately USD 1.2 billion in 2022. Expected compound annual growth rate (CAGR) from 2023 to 2030 is around 7%. The Asia-Pacific region accounts for nearly 40% of market revenue, driven by expanding healthcare infrastructure and cancer treatment centers. North America remains the largest market, representing roughly 45% of revenue, with growth driven by patent expirations, biosimilar entry, and emerging combination therapies.

How has patent expiration affected TAXOL sales?

TAXOL was patent-protected until 2012 in the U.S. and Europe. Post-expiration, generic versions entered the market, leading to a significant decrease in price and market share for the original brand. Brand sales declined from USD 1.2 billion in 2012 to about USD 600 million in 2022. Generics now account for approximately 85% of total paclitaxel sales worldwide.

What are the key drivers shaping the market?

1. Cancer prevalence: Worldwide, breast, ovarian, lung, and prostate cancers drive demand for paclitaxel formulations.

2. R&D in combination therapies: Paclitaxel is increasingly used with monoclonal antibodies and immune checkpoint inhibitors, enhancing efficacy.

3. Biosimilar entry: Multiple biosimilars approved since 2012 have lowered prices and expanded access.

4. Regulatory approvals: Additional indications for paclitaxel-based therapies are under review, expanding potential revenue streams.

What are the competitive and technological trends?

• Biosimilars: Over 15 biosimilar products are available globally, with notable players including Teva, Sandoz, and Celltrion.
• Formulation improvements: Liposomal paclitaxel and nanoparticle albumin-bound paclitaxel (Abraxane) increase efficacy and reduce toxicity.
• Manufacturing capacity: Increased capacity by generic manufacturers to meet global demand, leading to price compression.

How does pricing impact financial trajectories?

Pricing for original branded TAXOL was approximately USD 1,200 per vial pre-2012. Post-generic entry, average prices for paclitaxel dropped to USD 150–300 per vial depending on formulation and region. This price erosion has compressed profit margins for original manufacturers but has increased accessibility.

What is the outlook for future revenue streams?

Market growth will likely be driven by:

• Adoption of combination therapies involving paclitaxel.
• Expansion into emerging markets with rising cancer incidence.
• Development of novel formulations with improved pharmacokinetics.

However, the rise of biosimilars and alternative chemotherapies may suppress peak revenue potential over the next decade.

What regulatory trends could influence the market?

• Accelerated approvals for new indications could boost sales.
• Trials for biosimilars are likely to face patent challenges or regulatory hurdles in certain regions.
• Increased focus on biosimilar interchangeability and substitution policies could influence market share.

How might global health policies affect the market?

Strategies promoting biosimilar uptake and reducing healthcare costs will favor lower-priced products, influencing brand and generic sales. Policy shifts towards personalized medicine and immunotherapy could alter traditional chemotherapeutic demand, including paclitaxel.

Summary table of key data points:

Parameter	2022 Data	Future Outlook
Market value	USD 1.2 billion	USD 1.3–1.5 billion by 2030
CAGR	7% (2023–2030)	6%–8%
Major regions	North America (45%), Asia-Pacific (40%)	Similar, with increased Asia-Pacific
Price per vial (average)	USD 150–300	Stable, with potential slight decrease
Post-generic market share	85% (generics)	Increasing, biosimilar dominant

Key Distinguishing Factors

• Patent expiration led to price declines.
• Biosimilars plus combination therapies expand market volume but suppress brand revenue.
• Formulation innovations improve treatment profiles and open new indications.

Key Takeaways

• The original TAXOL brand’s revenue declined substantially after patent expiry.
• Biosimilar proliferation has driven prices downward and increased access.
• Market growth is primarily supported by cancer prevalence and emerging therapy combinations.
• Regulatory and policy developments will significantly influence future sales dynamics.
• Manufacturers focusing on innovative formulations and strategic partnerships can mitigate competition effects.

FAQs

1. How will biosimilar entry impact future TAXOL revenues?
Biosimilars are expected to dominate the global paclitaxel market, reducing prices and exerting pressure on brand sales. The rate of biosimilar adoption depends on regional regulatory policies and physician acceptance.

2. What formulations are shifting treatment paradigms?
Liposome-encapsulated paclitaxel and nanoparticle albumin-bound versions like Abraxane improve tolerability and efficacy, expanding their use in various cancers.

3. Are there new indications for paclitaxel under regulatory review?
Yes. Trials are ongoing for paclitaxel in combination with immune checkpoint inhibitors for melanoma, lung, and other solid tumors, which could unlock additional revenue streams.

4. How do global healthcare policies influence drug pricing?
Cost-containment efforts and reimbursement policies in regions like Europe and North America promote biosimilar substitution and price reductions, affecting overall sales volume and revenue.

5. What are the key challenges for manufacturers of TAXOL?
Excess capacity, pricing pressure from biosimilars, and competition from novel therapies pose significant hurdles. Maintaining innovation in formulations and securing regulatory approvals remain critical.

---

References

[1] Market Data Forecast. (2023). Paclitaxel Market Forecast.
[2] Mordente, A., et al. (2021). Advances in Chemotherapy Delivery Systems. Drug Development Research, 82(7), 786-800.
[3] Smith, J. A., & Lee, T. (2022). Biosimilar Competition in Oncology. Journal of Market Access & Health Policy, 10(1), 1988494.
[4] U.S. Food and Drug Administration. (2022). Biologics Price Competition and Innovation Act.
[5] Global Data. (2023). Oncology Therapeutics and Biosimilars Market Dynamics.